CB1 cannabinoid receptor inhibition: Promising approach for heart failure?

Congestive Heart Failure

Volumn 14, Issue 6, 2008, Pages 330-334

  Mukhopadhyay, Partha ^a   Mohanraj, Rajesh ^a   Bátkai, Sándor ^a   Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; ANANDAMIDE; AVE 1625; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DOXORUBICIN; ENDOCANNABINOID; OTENABANT; PLACEBO; RIMONABANT; SURINABANT; TARANABANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL MODEL; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART HEMODYNAMICS; HEART PROTECTION; HUMAN; HYPOTHERMIA; LIPOGENESIS; NAUSEA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RECEPTOR BLOCKING; SUICIDAL IDEATION; SURVIVAL RATE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; DRUG ANTAGONISM; DRUG EFFECT; HEART CONTRACTION; METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ENDOCANNABINOIDS; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK FACTORS;

EID: 57849091666     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.00016.x     Document Type: Article

References (40)

1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58: 389-462.
2. Liu J, Wang L, Harvey-White J, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2008; 54(1): 1-7.
3. Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov. 2008; 7(5): 438-455.
4. Bonz A, Laser M, Kullmer S, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol. 2003; 41(4): 657-664.
5. Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004; 110(14): 1996-2002.
6. Mukhopadhyay P, Batkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007; 50(6): 528-536.
7. Rajesh M, Mukhopadhyay P, Batkai S, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol. 2007; 293(4): H2210-H2218.
8. Rajesh M, Mukhopadhyay P, Hasko G, et al. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol. 2008; 153(2): 347-357.
9. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003; 112(3): 423-431.
10. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005; 54(10): 2838-2843.
11. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115(5): 1298-1305.
12. Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol. 2008; 294(1): G9-G12.
13. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005; 310(5746): 329-332.
14. Mendizabal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: A tale of passions and illusions. Br J Pharmacol. 2007; 151(4): 427-440.
15. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol. 2008; 153(2): 290-298.
16. Pacher P, Batkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol. 2005; 168: 599-625.
17. Bouchard JF, Lepicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci. 2003; 72(16): 1859-1870.
18. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2008; 153(2): 252-262.
19. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353(20): 2121-2134.
20. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365(9468): 1389-1397.
21. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet. 2006; 368(9548): 1660-1672.
22. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in ovArweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006; 295(7): 761-775.
23. Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008; 31(suppl 2): S229-S240.
24. Ruilope LM, Despres JP, Scheen A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens. 2008; 26(2): 357-367.
25. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial. JAMA. 2008; 299(13): 1547-1560.
26. Ungvari Z, Gupte SA, Recchia FA, et al. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005; 3(3): 221-229.
27. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358(20): 2148-2159.
28. Booz GW. PARP inhibitors and heart failure-translational medicine caught in the act. Congest Heart Fail. 2007; 13(2): 105-112.
29. Wagner JA, Hu K, Bauersachs J, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol. 2001; 38(7): 2048-2054.
30. Wagner JA, Hu K, Karcher J, et al. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol. 2003; 138(7): 1251-1258.
31. Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007; 46(1): 122-129.
32. Sommer C, Schomacher M, Berger C, et al. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol. 2006; 112(3): 277-286.
33. Muthian S, Rademacher DJ, Roelke CT, et al. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience. 2004; 129(3): 743-750.
34. Berger C, Schmid PC, Schabitz WR, et al. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem. 2004; 88(5): 1159-1167.
35. Kadoi Y, Goto F. Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: Comparison with norepinephrine. J Anesth. 2006; 20(4): 284-289.
36. Malfitano AM, Laezza C, Pisanti S, et al. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol. 2008; 153(5): 1003-1010.
37. Schafer A, Pfrang J, Neumuller J, et al. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol. 2008; 154(5): 1047-1054.
38. Despres JP. The endocannabinoid system: A new target for the regulation of energy balance and metabolism. Crit Pathw Cardiol. 2007; 6(2): 46-50.
39. Kunos G, Osei-Hyiaman D. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol. 2008; 294(5): G1101-G1104.
40. Poirier B, Bidouard JP, Cadrouvele C, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab. 2005; 7(1): 65-72.